Compare Fox Corp Class B (FOX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Viatris Inc — how do they compare? Fox Corp Class B trades at $55.42 (market cap $24.58B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Fox Corp Class B is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| FOX | VTRS | |
|---|---|---|
Market Cap | $24.58B | $18.69B |
Sector | Media | Health |
52-Week High | $67.76 | $17.86 |
52-Week Low | $44.39 | $9.49 |
Enterprise Value | $27.94B | $30.80B |
Dividend Yield | 1.05% | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
